You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
甘李藥業(603087.SH):博凡格魯肽(GZR18)注射液美國Ⅱ期臨牀試驗完成首例受試者給藥
格隆匯 03-10 16:51

格隆匯3月10日丨甘李藥業(603087.SH)公佈,公司自主研發的博凡格魯肽(研發代號:GZR18)注射液正在美國開展Ⅱ期臨牀試驗,於近日成功完成首例受試者給藥。博凡格魯肽(研發代號:GZR18)注射液是一種每兩週給藥一次的GLP-1RA,旨在治療成人2型糖尿病及肥胖/超重個體的體重管理。目前正在美國開展適應症爲肥胖/超重的Ⅱ期臨牀試驗,這也是全球首款與替爾泊肽頭對頭評估藥物減重療效的單靶點GLP-1RA。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account